Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Callan Capital LLC

Callan Capital LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 773 shares of the medical research company’s stock after buying an additional 20 shares during the period. Callan Capital LLC’s holdings in Thermo Fisher Scientific were worth $402,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. Prentice Wealth Management LLC increased its position in shares of Thermo Fisher Scientific by 7.2% during the fourth quarter. Prentice Wealth Management LLC now owns 1,040 shares of the medical research company’s stock worth $541,000 after purchasing an additional 70 shares in the last quarter. Bell Bank increased its position in shares of Thermo Fisher Scientific by 3.7% during the fourth quarter. Bell Bank now owns 1,789 shares of the medical research company’s stock worth $931,000 after purchasing an additional 63 shares in the last quarter. Greystone Financial Group LLC grew its holdings in shares of Thermo Fisher Scientific by 14.7% during the fourth quarter. Greystone Financial Group LLC now owns 3,700 shares of the medical research company’s stock valued at $1,925,000 after buying an additional 473 shares during the last quarter. Drum Hill Capital LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $338,000. Finally, Blackston Financial Advisory Group LLC grew its holdings in shares of Thermo Fisher Scientific by 9.1% during the fourth quarter. Blackston Financial Advisory Group LLC now owns 1,060 shares of the medical research company’s stock valued at $551,000 after buying an additional 88 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Scotiabank boosted their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday, February 3rd. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Bank of America dropped their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Citigroup upped their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a report on Friday, January 31st. Finally, Wells Fargo & Company upped their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $656.86.

Thermo Fisher Scientific Stock Down 1.0 %

TMO opened at $532.55 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $548.47 and a 200 day moving average price of $567.46. The company has a market cap of $203.70 billion, a PE ratio of 32.22, a price-to-earnings-growth ratio of 2.99 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.32%. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is 10.41%.

Thermo Fisher Scientific announced that its board has approved a share buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,125 shares of company stock worth $11,231,699 in the last 90 days. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.